AbbVie Inc. against Moderna, Inc. — live side-by-side technical comparison.
Prices as of 2026-09-23T20:03:50+00:00 UTC · updates daily
MRNA leads 4 of the 5 windows we measure — over 1 month ABBV is +0.2% and MRNA +31.1%; over year to date ABBV is +16.0% and MRNA +517.5%. The ABBV/MRNA price ratio stands at 1.4556, below its 50-day average of 3.011, and below the 200-day average of 4.3605. A ratio above its own average means ABBV is gaining on MRNA; on this reading the recent edge belongs to MRNA.
| ABBV | MRNA | |
|---|---|---|
| Price | $265.08 | $182.11 |
| 1 day | -0.1%lead | -0.2% |
| 5 days | +1.0% | +25.1%lead |
| 1 month | +0.2% | +31.1%lead |
| 6 months | +29.4% | +255.1%lead |
| Year to date | +16.0% | +517.5%lead |
| 52-week position | 95% of range | 94% of range |
| 52-week range | $190.75–$269.39 | $22.28–$192.31 |
| vs 50-day average | above $256.43 | above $104.86 |
| vs 200-day average | above $230.16 | above $62.57 |
| RSI (14) | 55 | 70 |
| Next earnings | 2026-10-29 | 2026-11-05 |
ABBV trades at $265.08, above its 50-day average of $256.43, and above the 200-day at $230.16. It sits at 95% of its 52-week range ($190.75–$269.39); 14-day RSI is 55, in neutral territory; an average session moves it about 2.1%. For levels, the first level overhead is $265.97 (0.3% away) and the first support below is $262.28 (1.1% down). On the checklist the page runs for every asset, 6 of 6 checks read bullish — the lean is bullish.
MRNA trades at $182.11, above its 50-day average of $104.86, and above the 200-day at $62.57. It sits at 94% of its 52-week range ($22.28–$192.31); 14-day RSI is 70, in overbought territory; an average session moves it about 6.3%. For levels, the first level overhead is $182.56 (0.2% away) and the first support below is $175.00 (3.9% down). On the checklist the page runs for every asset, 6 of 6 checks read bullish — the lean is bullish.
MRNA is the more volatile of the two — an average session moves it 6.3% against 2.1% for ABBV, so an identical position size carries roughly 3.0× the daily risk.
The comparison turns on those levels: ABBV clearing $265.97 or losing $262.28; MRNA clearing $182.56 or losing $175.00. Until one of them gives way, the relative reading above stands.